Cargando…

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sison, Edward Allan R., Magoon, Daniel, Li, Li, Annesley, Colleen E., Rau, Rachel E., Small, Donald, Brown, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253409/ https://www.ncbi.nlm.nih.gov/pubmed/25333254

Ejemplares similares

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
por: Sison, Edward Allan R., et al.
Publicado: (2015)

Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity
por: Cohen, Gordon, et al.
Publicado: (2020)

The Biology and Targeting of FLT3 in Pediatric Leukemia
por: Annesley, Colleen E., et al.
Publicado: (2014)

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
por: Annesley, Colleen E., et al.
Publicado: (2018)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression
por: Tsaouli, Georgia, et al.
Publicado: (2019)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12
por: Melo, Rita de Cássia Carvalho, et al.
Publicado: (2014)

Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5‐Fluorouracil
por: Wang, Dan, et al.
Publicado: (2018)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

Correction: CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12
Publicado: (2014)

Pediatric acute lymphoblastic leukemia
por: Inaba, Hiroto, et al.
Publicado: (2020)

Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia
por: Schraw, Jeremy M., et al.
Publicado: (2018)

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
por: Brandao, L N, et al.
Publicado: (2013)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia
por: Fries, Carol, et al.
Publicado: (2022)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow
por: Devi, Sapna, et al.
Publicado: (2013)

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor
por: Girbl, Tamara, et al.
Publicado: (2014)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2017)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Dysregulated Gene Expression in Lymphoblasts from Parkinson’s Disease
por: Annesley, Sarah Jane, et al.
Publicado: (2022)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia
por: Burke, Michael J., et al.
Publicado: (2014)

Bone morbidity in pediatric acute lymphoblastic leukemia
por: Ahn, Moon Bae, et al.
Publicado: (2020)

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2018)

Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia
por: Koyama, D, et al.
Publicado: (2014)

Trichosporon fungemia in a pediatric patient with acute lymphoblastic leukemia
por: Maxfield, Luke, et al.
Publicado: (2015)

Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia
por: Conneely, Shannon E., et al.
Publicado: (2020)

MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4
por: Hersi, Hersi Mohamed, et al.
Publicado: (2018)

Characterization and identification of leukemia initiating cells in pediatric acute lymphoblastic leukemia
por: Trentin, Luca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o80dodmq1p7505lql4vp31pkn0